Brokerages expect Omeros Co. (NASDAQ:OMER) to post earnings of ($0.63) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.57). Omeros posted earnings per share of ($0.25) during the same quarter last year, which would suggest a negative year over year growth rate of 152%. The business is scheduled to announce its next earnings report on Thursday, March 7th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($2.67) per share for the current fiscal year, with EPS estimates ranging from ($2.71) to ($2.62). For the next fiscal year, analysts expect that the company will report earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Omeros.
Omeros (NASDAQ:OMER) last released its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The business had revenue of $4.61 million during the quarter, compared to analysts’ expectations of $3.07 million. During the same quarter last year, the firm earned ($0.16) earnings per share.
NASDAQ:OMER traded down $0.01 during mid-day trading on Friday, hitting $13.95. The company had a trading volume of 419,350 shares, compared to its average volume of 895,182. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.00. The firm has a market capitalization of $684.17 million, a price-to-earnings ratio of -17.66 and a beta of 3.79.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Omeros by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,204,427 shares of the biopharmaceutical company’s stock worth $53,810,000 after purchasing an additional 34,043 shares during the period. Morgan Stanley raised its position in shares of Omeros by 2.1% during the third quarter. Morgan Stanley now owns 283,507 shares of the biopharmaceutical company’s stock worth $6,920,000 after purchasing an additional 5,967 shares during the period. TIAA CREF Investment Management LLC raised its position in shares of Omeros by 1.8% during the third quarter. TIAA CREF Investment Management LLC now owns 244,374 shares of the biopharmaceutical company’s stock worth $5,965,000 after purchasing an additional 4,260 shares during the period. Teachers Advisors LLC raised its position in shares of Omeros by 35.6% during the third quarter. Teachers Advisors LLC now owns 116,400 shares of the biopharmaceutical company’s stock worth $2,841,000 after purchasing an additional 30,544 shares during the period. Finally, Advisors Asset Management Inc. acquired a new stake in shares of Omeros during the third quarter worth about $301,000. 48.48% of the stock is currently owned by institutional investors.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.